FENATROL

Fenofibrate USP

Composition : Fenofibrate USP 145 mg Tablet.

Indication : Fenofibrate is indicated as an adjunctive therapy to diet for the treatment of adults with hypertriglyceridemia (Types IV and V hyperlipidemia). Fenofibrate is also indicated in hypercholesterolemia or, mixed Dislipidemia (type II hyperlipidemia).

Dosage and administration : For the treatment of adult patients with hypercholesterolemia or mixed hyperlipidemia, the initial dose of Fenatrol is 200 mg per day. For adult patients with hypertriglyceridemia, the initial dose is 67 to 200 mg per day. Dose should be individualized according to patient response. Fenatrol should be given with meal there by, optimizing the bioavailability of the medication. Or, as directed by the registered physician.

Packing : Fenatrol-145 :  3 x 10's Tablet in blister pack.

PRESCRIBING DESCRIPTION

Composition : Fenofibrate 145mg & 200mg Capsule. Indications : Fenofibrate is indicated as an adjunctive therapy to diet for the treatment of adults with hypertriglyceridemia (Types IV and V hyperlipidemia). Fenofibrate is also indicated in hypercholesterolemia or, mixed Dislipidemia (type II hyperlipidemia). Dosage & administration : For the treatment of adult patients with hypercholesterolemia or mixed hyperlipidemia, the initial dose of Fenatrol is 200mg per day. For adult patients with hypertriglyceridemia, the initial dose is 67 to 200 mg per day. Dose should be individualized according to patient response. Fenatrol should be given with meal there by, optimizing the bioavailability of the medication. Or, as directed by the registered physician. Side effects : Common adverse events (occurring in 6% of patients) were gastrointestinal symptoms, muscle pain, and skin problems such as skin rash, sweating. Contraindications : Fenofibrate is contraindicated in patients with severe renal, or hepatic dysfunction existing gallbladder disease and in patients with hypersensitive to Fenofibrate. Pregnancy and lactation : Pregnancy Category-C by FDA. Precautions : Fenofibrate may increase the risk of pancreatitis and myopathy. hematologic Change like thrombocytopenia and agranulocytosis have been reported rarely. Drug interactions : Fenofibrate has been reported to potentiate the anticoagulant effects of warfarin. Fenofibrate may increase the nephrotoxicity of cyclosporine. Cautions should be taken against the use of Fenofibrate with HMG-CoA reductase inhibitors. Packing : Fenatrol-145 : 3 x 10's Tablet in blister pack. Fenatrol-200 : 3 x 10's Capsule in blister pack.